Table 2 Mendelian randomization results of lipid-lowering drug genetic variants in target genes from the UK Biobank database with risk of IBD from the database of de Lange et al.

ABCG5 (APOB)

WM

0.78 (0.54- 1.14)

0.2

0.82 (0.53- 1.26)

0.37

0.61 (0.36- 1.03)

0.07

IVW

0.84 (0.64- 1.12)

0.23

0.92 (0.66- 1.31)

0.66

0.83 (0.52- 1.30)

0.41

ABCG5 (LDL)

WM

0.77 (0.54- 1.09)

0.14

0.85 (0.56- 1.30)

0.46

0.62 (0.38- 1.02)

0.06

IVW

0.83 (0.64- 1.09)

0.19

0.93 (0.68- 1.27)

0.64

0.79 (0.52- 1.22)

0.29

APOB (LDL)

WM

1.07 (0.89- 1.28)

0.47

0.98 (0.75- 1.27)

0.86

1.09 (0.87- 1.36)

0.46

IVW

0.98 (0.86- 1.12)

0.75

0.88 (0.71- 1.08)

0.22

1.07 (0.91- 1.25)

0.44

APOB (APOB)

WM

0.99 (0.85- 1.15)

0.9

0.93 (0.77- 1.13)

0.47

0.98 (0.82- 1.17)

0.8

IVW

0.97 (0.88- 1.08)

0.62

0.87 (0.75- 1.00)

0.05

1.07 (0.94- 1.22)

0.32

APOC3 (APOB)

WM

0.59 (0.39- 0.90)

1.50E-02

0.46 (0.26- 0.82)

8.40E-03

0.78 (0.48- 1.27)

0.32

IVW

0.52 (0.38- 0.69)

9.90E-06

0.41 (0.27- 0.63)

5.10E-05

0.67 (0.46- 0.97)

3.50E-02

APOC3 (TG)

WM

0.89 (0.79- 1.01)

0.06

0.90 (0.78- 1.04)

0.16

0.94 (0.82- 1.07)

0.35

IVW

0.87 (0.80- 0.95)

2.30E-03

0.83 (0.73- 0.94)

2.80E-03

0.90 (0.81- 0.99)

3.70E-02

HMGCR (APOB)

WM

0.69 (0.47- 1.00)

5.00E-02

0.74 (0.44- 1.25)

0.26

0.57 (0.36- 0.90)

1.50E-02

IVW

0.68 (0.52- 0.91)

8.70E-03

0.76 (0.45- 1.29)

0.31

0.64 (0.44- 0.92)

1.50E-02

HMGCR (LDL)

WM

0.70 (0.50- 0.97)

3.10E-02

0.73 (0.47- 1.12)

0.15

0.64 (0.42- 0.98)

3.80E-02

IVW

0.72 (0.56- 0.92)

8.70E-03

0.76 (0.52- 1.11)

0.15

0.68 (0.50- 0.94)

1.80E-02

LDLR (APOB)

WM

1.16 (0.95- 1.43)

0.15

0.90 (0.69- 1.17)

0.43

1.53 (1.16- 2.01)

0.0026

IVW

1.20 (1.04- 1.38)

1.10E-02

0.89 (0.74- 1.08)

0.24

1.43 (1.19- 1.71)

1.30E-04

LDLR (LDL)

WM

1.17 (0.95- 1.43)

0.14

0.90 (0.70- 1.16)

0.43

1.48 (1.14- 1.94)

0.0036

IVW

1.18 (1.03- 1.36)

1.80E-02

0.90 (0.75- 1.07)

0.24

1.40 (1.17- 1.67)

2.60E-04

LPL (APOB)

WM

1.95 (1.11- 3.43)

2.00E-02

1.50 (0.72- 3.12)

0.27

2.42 (1.18- 4.95)

1.60E-02

IVW

2.10 (1.35- 3.28)

1.10E-03

1.64 (0.93- 2.90)

0.09

2.55 (1.44- 4.53)

1.30E-03

LPL (TG)

WM

1.17 (1.02- 1.33)

2.00E-02

1.08 (0.92- 1.28)

0.33

1.19 (1.01- 1.41)

4.00E-02

IVW

1.20 (1.09- 1.33)

1.70E-04

1.12 (0.99- 1.27)

0.06

1.26 (1.11- 1.43)

2.60E-04

NPC1L1 (APOB)

WM

1.85 (0.78- 4.39)

0.17

1.64 (0.56- 4.76)

0.37

2.50 (0.80- 7.86)

0.12

IVW

2.15 (0.93- 4.99)

0.07

2.04 (0.84- 4.94)

0.12

2.07 (0.65- 6.61)

0.22

NPC1L1 (LDL)

WM

1.68 (0.84- 3.34)

0.14

1.65 (0.67- 4.06)

0.28

2.84 (1.07- 7.59)

3.70E-02

IVW

1.94 (1.04- 3.61)

3.70E-02

1.91 (0.92- 3.96)

0.08

1.63 (0.65- 4.11)

0.3

PCSK9 (APOB)

WM

1.00 (0.76- 1.31)

0.98

1.13 (0.79- 1.61)

0.5

0.75 (0.52- 1.09)

0.13

IVW

0.87 (0.70- 1.07)

0.18

1.01 (0.78- 1.29)

0.96

0.72 (0.54- 0.95)

2.00E-02

PCSK9 (LDL)

WM

1.00 (0.76- 1.31)

0.98

1.13 (0.80- 1.60)

0.49

0.76 (0.53- 1.08)

0.12

IVW

0.88 (0.72- 1.07)

0.2

1.02 (0.80- 1.30)

0.87

0.73 (0.56- 0.96)

2.20E-02

PPARA (TG)

Wald ratio

2.20 (0.41–11.85)

0.36

3.25 (0.38–27.68)

0.28

2.40 (0.28- 20.91)

0.43